GTB Naturals And Holistics Inc

11/17/2022

TESTIMONIAL FOR
RHEUMATOID ARTHRITIS
SWELLING ON THE BODY
IRREGULAR HEART BEATS
INSOMNIA, HEADACHES
SHORT OF BREATH AND
MANY OTHER ISSUES
VERY DRY SKIN

GOOD MORNING,
MY NAME IS AMANDEEP AND I AM LIVING IN CALGARY FOR THE LAST 25 YEARS, THIS IS A FREE TESTIMONIAL FOR DOCTOR AHLUWALIA AND IT IS NOT A PAID ADVERTISEMENT OF ANY KIND
I FELT BLESSED ENOUGH TO GET THE CONTACT NUMBER OF DR. AHLUWALIA FROM ONE OF MY FRIENDS. I WAS HAVING A NUMBER OF HEALTH ISSUES WHEN I CAME TO SEE DR. AHLUWALIA
I WAS DIAGNOSED WITH RHEUMATOID ARTHRITIS COUPLE OF YEARS BEFORE AND IUSED TO FEEL THE PAIN IN MY FEET, KNEES, FINGERS
AND SOMETIMES IN THE WHOLE BODY,
IN ADDITION TO THAT I HAD THE FOLLOWING ISSUES AS WELL
ALWAYS HAVE LITTLE HEADACHES AND SEVERE HEADACHE ONCE IN A WEEK
SWELLING ON FACE, BODY, LEGS AND FEET
WATERY EYES, ITCHY EYES AND BLURRY EYES
DRY MOUTH, WAS NOT ABLE TO SMELL THE THINGS
INSOMNIA WITH LOW QUALITY SLEEP
WATER COMES OUT THE MOUTH DURING MY SLEEP, SHORT OF BREATH, LOW ENERGY
IRREGULAR HEART BEATS, LOW APPETITE AND CRAVINGS FOR THE SUGAR
VERY DRY SKIN, ITCHY ON THE WHOLE BODY, UNUSUAL SMELL FROM THE BODYMY BEFORE AND AFTER PICTURES ARE ATTACHES AS WELL
MY INITIAL CONSULTATION WITH DR AHLUWALIA WAS FULL OF EDUCATION REGARDING THE CAUSES OF THE DISEASES, HOW THESE DISEASES ARE IMPACTING THE HUMAN BODY AND WHAT CAN WE DO TO ELIMINATE THEM.
IT WAS QUITE INSPIRING AS I WAS TAKING NUMBER OF PILLS AND EVEN THESE PILLS SEEMS TO BE INEFFECTIVE IN HELPING ME OUT WITH THESE PROBLEMS WHICH WERE ON THEIR RISING SCALE WITH THE PASSING OF EACH YEAR.
THE KNOWLEDGE AND SKILLS OF DR. AHLUWALIA MAKE HIM DISTINGUISHED AMONG THE OTHERS, AFTER GETTING HIS TREATMENT FOR TWO WEEKS ONLY
THE PAINS FROM MY BODY, KNEES, FEET AND FINGERS DISAPPEARED AND I AM NOT TAKING ANY MEDICATION FOR MY RH AS WELL FOR THE LAST 2 WEEKS NOW, ACTUALLY I WAS FEELING BETTER ONLY AFTER THE FOURTH DAY OF HIS TREATMENT, AMAZING!
SWELLING FROM MY BODY, MY SKIN TEXTURE, MY SLEEPLESS NIGHTS SEEMS TO BE A THING OF PAST
HEART BEATS LOOKS LIKE THEY WERE NEVER OUT OF THEIR RHYTHM. NO MORE HEADACHES, NO MORE WATERY AND ITCHY EYES,
IN FACT, I HAVE IMPROVED A LOT AND ACHIEVED THE VERY NEXT LEVEL OF MY HEALTH AND WELLNESS AS I HAVE RECEIVED THE VERY BEST OF PROFESSIONAL CARE FROM DR. AHLUWALIA
I AM SO EXCITED THAT I AM A DISEASE-FREE AND PILL FREE PERSON HAVING A FULL CHARGE OF MY HEALTH, AS DR. AHLUWALIA ADVOCATES TO ALL HIS PATIENTS
A DOCTOR WITH ZERO GREED FOR MONEY AND THE RHEUMATOID PAIN LISTENS TO HIM WHATEVER HE SAYS. HaHaHaHa AS I TEASE HIM

THANK YOU TO DR. AHLUWALIA WHO HAS PROVIDED ME WITH ALL THE COMFORT AND CARE TO OVERCOME MY SO MANY DISEASES, YOU CAN CONTACT ME AT 403 9190 3471 FOR ANY OTHER INFORMATION.
BEFORE AND AFTER PICTURES BELOW

02/03/2019

05/19/2018

ACP recommends less intensive glucose control in most cases of type 2 diabetes

Guidance statement authors cited concerns that targeting HbA1c levels below 7% may increase risk for death, weight gain, hypoglycemia, and other adverse effects.

All articles from the March 6, 2018, ACP Internist Weekly Newsletter
________________________________________
Most patients with type 2 diabetes should aim for an HbA1c target between 7% and 8% rather than 6.5% to 7%, according to a new evidence-based guidance statement from ACP.

Glycemic control may be finely balanced for many persons and vary according to expected duration of treatment, co-morbid conditions, risk factors for hypoglycemia, and choice of medication,” the guidance authors wrote.

“The choice of glycemic target also depends on consideration of other variables, such as risk for hypoglycemia, weight gain, and other drug-related adverse effects, as well as the patient's age, life expectancy, other chronic conditions, functional and cognitive impairments, fall risk, ability to adhere to treatment, and medication burden and cost.”

ACP recommends that clinicians aim for an HbA1c level between 7% and 8% in most patients with type 2 diabetes.

The authors of the guidance statement noted concerns that targeting HbA1c levels below 7% may increase risk for death, weight gain, hypoglycemia, and other adverse effects.

They also noted that while guidelines recommending lower targets do so based on the rationale that intensive glycemic control reduces micro vascular events over years of treatment, the evidence to support this potential benefit is inconsistent.

More stringent targets may be appropriate for patients with a long life expectancy who are interested in more intensive Glycemic control with pharmacologic therapy, despite risk for harms, the authors wrote. In patients with type 2 diabetes who have achieved HbA1c levels below 6.5%, ACP recommends that clinicians consider de intensifying pharmacologic therapy.

Finally, ACP recommends that clinicians should treat patients with type 2 diabetes to minimise symptoms related to hyperglycemia and avoid targeting a specific HbA1c level in patients with a life expectancy of less than 10 years because of advanced age, residence in a nursing home, or chronic conditions.

ACP concluded that the harms of therapy outweigh the benefits in these cases. “Setting stringent targets in these populations is not an optimal approach, and clinicians should instead focus on treating to reduce symptoms from both disease and treatment,” the authors wrote.